For the past decade, Harris Bricken attorneys have advised domestic and international businesses and entrepreneurs on rapidly evolving laws and regulations in the cannabis, hemp, and regulated substances industries.
Over the last few years, our attorneys have led the way on advising investors, businesses, and entrepreneurs in emerging drug therapies – psilocybin, ketamine infusion clinics, MDMA and other psychedelic substances. We discussed these topics live back on July 9, and now, by popular demand, we will be hosting a follow up webinar.
On Thursday, November 19, 2020 at 12pm PT, Harris Bricken attorneys will address the results of the elections and other recent developments related to psychedelic drugs and new drug therapies. We will look at the process and results for Measure 109 (psilocybin licensing) and Measure 110 (controlled substance decriminalization) in Oregon, as well as future efforts to decriminalize, protect and regulate psychedelic drug use. The conversation will cover everything from religious exemptions to commercial opportunities.
The panel will be moderated by Vince Sliwoski (Portland), with panelists Griffen Thorne (Los Angeles), Alison Malsbury (San Francisco), and Jesse Mondry (Portland). The panelists will take questions throughout the presentation.
The post FREE Webinar on November 19th: Ketamine, Psilocybin and New Drug Therapies, Part 2! appeared first on Harris Bricken.